In gastric cancer cells, GRg3 combined with cisplatin modulates the Wnt/β-catenin signaling pathway, downregulates the expression of pathway-associated proteins (Wnt, β-catenin, C-myc, and cyclin D1) and EMT-associated proteins, significantly inhibits the activity of SGC-7901 cells, increases cisplatin-induced apoptosis, enhances the sensitivity of gastric cancer cells to cisplatin chemotherapy, enhances the efficacy of chemotherapy, and inhibits the malignant progression of tumors (12). This evidence concerns the gene MYC and gastric cancer.